Optimal Therapeutic Strategy for Non-small Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor
10.3779/j.issn.1009-3419.2015.02.11
- VernacularTitle:EGFR敏感突变NSCLC患者的最佳治疗模式探讨
- Author:
SHI ZHONG
1
;
FAN YUN
Author Information
1. 浙江省肿瘤医院化疗中心
- Keywords:
Lung neoplasms;
EGFR-TKI;
Chemotherapy;
Bevacizumab
- From:
Chinese Journal of Lung Cancer
2015;(2):110-116
- CountryChina
- Language:Chinese
-
Abstract:
Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used in non-small cell lung cancer (NSCLC) patients, it is still controversial about how to combine EGFR-TKI with chemo-therapy and other targeted drugs. We have made a summary on the current therapeutic models of EGFR-TKI combined with chemotherapy/bevacizumab in this review and aimed to ifnd the optimal therapeutic strategy for NSCLC patients with EGFR mutation.
